This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
30 Sep 2026 consolidated revenue up 652%, profit after tax up 435% year on year
SHUKRAPHAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations rose 652% to Rs 4,420.38 lakh from Rs 587.74 lakh a year earlier, while profit after tax rose 435% to Rs 1,271.19 lakh from Rs 237.81 lakh. The operating margin before other income, interest, tax and depreciation rose from negative 7.1% to 42.3%. Consolidated half-year operating cash flow was positive Rs 43.31 lakh. Earlier figures were regrouped or reclassified.
Strong revenue and profit growth may support the share price, but the small prior-year base and low half-year operating cash flow add risk.
The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹44.20 Cr against ₹5.88 Cr a year ago, about 8× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.